No-cost, comprehensive next-generation sequencing for eligible mNSCLC patients
Lilly is sponsoring Tempus sequencing to reduce disparities in biomarker testing. Through this program, Lilly is offering no-cost, comprehensive next-generation sequencing (NGS) for eligible advanced or metastatic non-small cell lung cancer (NSCLC) patients. Research demonstrates that ~47% of patients with lung adenocarcinoma have an actionable genomic alteration and may benefit from appropriate targeted therapy.1 Only ~50% of metastatic NSCLC patients in community practices are consistently being tested for the five common biomarkers ALK, BRAF, EGFR, PD-L1, and ROS1.2
There is no obligation to order any other Lilly or Tempus product or service in order to participate in the sponsored test program. To enroll a patient, please use the program requisition form and follow the steps below.
This is the future of healthcare.